![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Procter and Gamble |
---|---|
Information provided by: | Procter and Gamble |
ClinicalTrials.gov Identifier: | NCT00071422 |
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Non-Insulin-Dependent |
Drug: INGAP-Peptide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 35 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
United States, California | |
Diabetes and Endocrine Associates | |
La Jolla, California, United States, 92037 | |
Diablo Clinical Research | |
Walnut Creek, California, United States, 94598 | |
VA Hospital UCSD | |
San Diego, California, United States, 92161 | |
United States, Colorado | |
Longmont Medical Research Network | |
Longmont, Colorado, United States, 80501 | |
Denver, Colorado, United States, 80209 | |
United States, District of Columbia | |
MedStar Clinical Research Center | |
Washington, District of Columbia, United States, 20003 | |
United States, Massachusetts | |
Future Care Studies | |
Springfield, Massachusetts, United States, 01107 | |
United States, Montana | |
Mercury Street Medical | |
Butte, Montana, United States, 59701 | |
United States, New York | |
Diabetes-Endocrinology Center of WNY | |
Buffalo, New York, United States, 14209 | |
United States, North Carolina | |
Piedmont Medical Group | |
Winston Salem, North Carolina, United States, 27103 | |
UNC Diabetes Care Center | |
Durham, North Carolina, United States, 27713 | |
United States, Oregon | |
Clinical Research Institute of Southern Oregon | |
Medford, Oregon, United States, 97504 | |
United States, South Carolina | |
Mountain View Clinical Research | |
Greer, South Carolina, United States, 29651 | |
United States, Texas | |
Dallas Diabetes and Endocrine Center | |
Dallas, Texas, United States, 75230 | |
DGD Research Associates | |
San Antonio, Texas, United States, 78229 | |
University of Texas Health Science Center - Texas Diabetes Institute | |
San Antonio, Texas, United States, 78207 | |
United States, Virginia | |
Charlottesville Medical Research | |
Charlottesville, Virginia, United States, 22911 |
Study ID Numbers: | 2003069 |
Study First Received: | October 22, 2003 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00071422 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Type 2 diabetes |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders |